BPC-157 and TB-500 are the two peptides most often discussed in repair-focused research. They are structurally and biologically different, and they are sometimes studied together. Both are research-use-only compounds — not approved for human use. Here’s how they compare.
- BPC-157: a 15-amino-acid peptide derived from a gastric-juice protein.
- TB-500: a synthetic peptide related to the actin-binding protein Thymosin β4.
- Different mechanisms: distinct origins and proposed pathways.
- Status: neither is FDA-approved; both are research use only.
Side-by-side comparison
| BPC-157 | TB-500 | |
|---|---|---|
| Type | Pentadecapeptide (15 aa) | Thymosin β4 fragment |
| Origin | Gastric-juice protein sequence | Actin-binding protein |
| Proposed focus | Angiogenesis, GI & tendon models | Actin regulation, cell migration |
| Lab form | Lyophilized powder | Lyophilized powder |
| Status | Research only | Research only |
How they differ
The two are easy to confuse because both appear in tissue-repair literature, but they approach it differently. BPC-157 research emphasizes angiogenesis and gastrointestinal models, while TB-500 research centers on actin dynamics and cell migration. Because the proposed mechanisms are complementary rather than overlapping, researchers sometimes examine them in combination.
- BPC-157 — see the full BPC-157 research overview.
- TB-500 — see the full TB-500 research overview.
Studied together
Because their proposed pathways differ, some research uses both as a single material — the BPC-157 / TB-500 blend. Individual compounds are also available: BPC-157 and TB-500.
Research status
Neither BPC-157 nor TB-500 is approved by the FDA for human use, and both are prohibited in competitive sport. The available evidence is preclinical. Treat both strictly as research compounds.
Compare both research-grade compounds
Lab-tested, with third-party purity verification.